GlassScriptPhysician profile
Brett J Eliuk
NPI 1871714915
$17,630.20
in general payments reported to CMS, 2019-2025
24 companies · $284 in 2025
The $284 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,326 · 2020: $2,367 · 2021: $5,219 · 2022: $2,046 · 2023: $3,602 · 2024: $787 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,183 · Food and Beverage: $1,490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,183.34 |
| Food and Beverage | $1,489.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $7,945.66 | 2019-2025 | Aveir |
| Boston Scientific Corporation | $5,318.95 | 2019-2025 | Watchman Flx, Patientcare Link |
| Medtronic, INC. | $1,684.81 | 2021-2025 | Azure Xt Dr Mri Surescan, Selectsecure, Micra |
| Medtronic Vascular, INC. | $1,007.07 | 2019 | |
| Novartis Pharmaceuticals Corporation | $404.01 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $323.04 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $218.05 | 2019-2024 | Camzyos |
| Amgen INC. | $123.65 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $116.18 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $65.21 | 2019 | |
| Pfizer INC. | $56.84 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $49.25 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $46.02 | 2019-2023 | Farxiga |
| Amarin Pharma, INC. | $43.33 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $35.18 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Advanced Respiratory, INC | $34.45 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.69 | 2021-2022 | |
| Argon Medical Devices, INC. | $22.54 | 2025 | Clot Management |
| Astellas Pharma US INC | $20.38 | 2020 | |
| Merck Sharp & Dohme LLC | $18.34 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $17.56 | 2022 | |
| Daiichi Sankyo INC. | $16.23 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $15.44 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Eliuk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.